Replidyne, Inc. (Nasdaq: proposed RDYN) intends to offer up to Wall St. 5 million shares priced between $14 and $16 in next weeks highly anticipated IPO. What makes me exceedingly bullish on this offering is that unlike many biotech IPO’s that transpire in the midst of Phase II or III and sometimes even during Phase I clinical trials, Replidyne has filed an NDA with the FDA for its lead product Orapem™, the pipeline is robust, partnerships with bigphamra are strong and, the management team lead by Ken Collins has proven to be outstanding.
Friday, June 23, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment